Pilot study of an endoluminal-suturing device as a treatment for patients with gastroesophageal reflux disease
Endoscopy International Open · 01.11.2023 · 11 (11) · E1092-E1098
DOI: 10.1055/a-2185-5947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 01.11.2023. Verfasst von Hubert Louis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles (H.U.B.), C.U.B. Hôpital Erasme, Université Libre de…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and study aims Endoscopic therapy is a promising option for patients with gastroesophageal reflux disease (GERD). The aim of this study was to assess safety and feasibility of the Endomina suturing platform as a treatment for GERD. Patients and methods This was a two-center study of patients with chronic GERD symptoms that responded at least partially to proton pump inhibitors (PPIs). Primary endpoints were to assess the safety of the procedure and persistence of the sutures. Secondary endpoints were to assess esophageal pH-impedance and manometry parameters changes at 6 months, as well as GERD symptoms and PPI use up to 12 months of follow-up.
Results
Fourteen patients were treated (13 males, mean of 43±12 years), with a mean number of three plications per patient. Thirteen, 10, and nine patients were analyzed at 3, 6, and 12 months of follow-up, respectively. One device-related adverse event occurred (loss of needle tip requiring endoscopic retrieval 1 week later). A mean of two plications persisted at 3 and 12 months. A decrease in median acid exposure time and reflux episodes was observed after the procedure. Mean Reflux Symptom Index and GERD-Health-Related Quality of Life scores decreased during follow-up visits and 90% of the patients discontinued PPI use at 1 year.
Conclusions
Endoscopic full-thickness suturing of the esophagogastric junction with the Endomina suturing platform is feasible, allowing persistence of two-thirds of the plications, with promising results for decreasing reflux and improving GERD symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles (H.U.B.), C.U.B. Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.
- Endo Tools Therapeutics, Gosselies, Belgium.
- Department of Biomedical Research, Université Libre de Bruxelles, Bruxelles, Belgium.
- Digestive Diseases Unit, Champalimaud Foundation, Lisboa, Portugal.
ORCID-Profile: Vincent Huberty
Zitieren
APA
Louis, H., Van Ouytsel, P., Leclercq, L., Houinsou Hans, M., Devière, J., Rio-Tinto, R., & Huberty, V. (2023). Pilot study of an endoluminal-suturing device as a treatment for patients with gastroesophageal reflux disease. Endoscopy International Open, 11(11), E1092-E1098. https://doi.org/10.1055/a-2185-5947
Vancouver
Louis H, Van Ouytsel P, Leclercq L, Houinsou Hans M, Devière J, Rio-Tinto R, et al. Pilot study of an endoluminal-suturing device as a treatment for patients with gastroesophageal reflux disease. Endoscopy International Open. 2023;11(11):E1092-E1098. doi:10.1055/a-2185-5947
BibTeX
@article{Louis2023,
author = {Louis, Hubert and Van Ouytsel, Pauline and Leclercq, Loulia and Houinsou Hans, Mélina and Devière, Jacques and Rio-Tinto, Ricardo and Huberty, Vincent},
title = {Pilot study of an endoluminal-suturing device as a treatment for patients with gastroesophageal reflux disease},
journal = {Endoscopy International Open},
year = {2023},
volume = {11},
number = {11},
pages = {E1092--E1098},
doi = {10.1055/a-2185-5947}
}
EUVIMED